The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
HIV Assembly, Transport, Egress And Transfer From Infected Dendritic Cells
Funder
National Health and Medical Research Council
Funding Amount
$511,629.00
Summary
HIV-AIDS is the fourth leading killing disease worldwide, with the disease burden shifting towards women. Study of the HIV life cycle in cells known to be targetted during HIV transmission is key towards designing additional preventative measures in the form of topical gels known as microbicides. Mapping of the basic pathways of viral transport within such cells, will aid further drug discovery and-or appropriateness of use of existing drugs in microbicide formulations.
Viral And Cellular Factors Affecting Early Steps In HIV Reverse Transcription
Funder
National Health and Medical Research Council
Funding Amount
$465,750.00
Summary
One of the key events in the life cycle of HIV is the conversion of viral RNA into a double stranded DNA intermediate. This process, called reverse transcription, is carried out by the viral enzyme reverse transcriptase (RT) in conjunction with other viral and cellular factors. While HIV RT has been extensively studied and RT inhibitors have been used in anti-retroviral therapy for HIV patients, other viral and cellular factors essential for efficient HIV reverse transcription have not been prop ....One of the key events in the life cycle of HIV is the conversion of viral RNA into a double stranded DNA intermediate. This process, called reverse transcription, is carried out by the viral enzyme reverse transcriptase (RT) in conjunction with other viral and cellular factors. While HIV RT has been extensively studied and RT inhibitors have been used in anti-retroviral therapy for HIV patients, other viral and cellular factors essential for efficient HIV reverse transcription have not been properly investigated and may represent a new class of anti-HIV targets.This project, based on our long standing (>10 years) research interest and experience, aims at identification of the viral and cellular factors particularly involved in the early steps of HIV reverse transcription.We have obtained preliminary data which lead to hypotheses regarding what kind of viral and cellular factors might be involved and their possible modes of action. Experiments have been designed to specifically prove or disprove these hypotheses. Thus this project will help us achieve a more comprehensive understanding on how HIV uses other viral and cellular factors, in addition to RT, to accomplish one of the mandatory stage of its growth (reverse transcription); and identify viral and cellular factors which can be further explored as new targets for anti-retroviral therapy. This is particularly important, as HIV resistance to current drug therapy has emerged as one serious issue facing HIV patients, and the HIV care communities.Read moreRead less
Even in well-resourced countries, the ability to continue treating HIV patients for their lifetime may become unaffordable, which has focused attention on developing a cure for HIV. We have exploited unique insights into a pathway for Tat expression from latent HIV to identify novel compounds that target HIV latency. This project assembles a multidisciplinary team to optimize the lead compounds, and develop novel drug regimens to fast-track into clinical development as a HIV-curative therapy.
HIV-1 infection is characterised by high levels of virus replication and a progressive loss of immune cells, particularly CD4+ T lymphocytes. Highly active antiretrovial therapy (HAART) for HIV-1 infection results in profound suppression of viral replication, a substantial increase in CD4+ T lymphocytes and a decrease in morbidity and mortality. The primary source of T lymphocytes in early human development is the thymus. Recently, it has been demonstrated that the thymus remains functional thro ....HIV-1 infection is characterised by high levels of virus replication and a progressive loss of immune cells, particularly CD4+ T lymphocytes. Highly active antiretrovial therapy (HAART) for HIV-1 infection results in profound suppression of viral replication, a substantial increase in CD4+ T lymphocytes and a decrease in morbidity and mortality. The primary source of T lymphocytes in early human development is the thymus. Recently, it has been demonstrated that the thymus remains functional throughout adult life. The role of the thymus in HIV-1 infection remains controversial. Studies of the role of the thymus in HIV-1-infected individuals has been limited by the lack of a marker of thymic function in vivo. We have recently developed a novel assay to quantify cells of recent thymic origin by taking advantage of certain molecular events that occur in the thymus during the production of new T lymphocytes. This molecular event creates a circular piece of DNA, called a T-cell receptor excision circles (TREC). TREC concentration in the periphery will increase with an increase in thymic output but will reduce in the presence of T cell proliferation or cell death. In order to determine the contribution of the thymus to immune reconstitution following HAART, we plan to study the dynamics of thymus function in HIV-1 infection by measuring TREC and T cell turnover in HIV-1 infection prior to and following HAART. In a subgroup of individuals, more commonly seen following treatment of HIV-1 infection in children, there is an increase in CD4+ T lymphocytes in the absence of a significant reduction in viral suppression. The role of the thymus in this unique subset of individuals will be studied.Read moreRead less
A Longitudinal Study Of Natural Killer Cell Function In HIV-infected Individuals Initiating Therapy
Funder
National Health and Medical Research Council
Funding Amount
$620,176.00
Summary
HIV infected people no longer die from AIDS but suffer and die from non-AIDS conditions such as non-AIDS related cancers. We have discovered persistent abnormalities in natural killer cells in HIV patients receiving antiretroviral therapy. These cells help prevent the development of and control cancers so understanding why they are abnormal in HIV patients will help prevent early death from non-AIDS cancers.
CD4+ T-cells In HIV - Regulator Or Target Of Viral Infection: A Modelling Approach
Funder
National Health and Medical Research Council
Funding Amount
$319,740.00
Summary
T-cell loss due to HIV infection causes immunodeficiency. Since virus grows faster if more T-cells are available and preferentially infects dividing cells, we want to understand how replacement, division and death of uninfected T-cells affect the progress of HIV infection and T-cell recovery during drug therapy. The results of our study will lead to a better understanding of HIV disease, and may assist in the development of novel treatment regimes optimising T-cell numbers during infection.
The Role Of Vif In Enhancing HIV Replication And Effecting The Integrity Of The Replication Complexes Of HIV
Funder
National Health and Medical Research Council
Funding Amount
$260,200.00
Summary
HIV-AIDS is still one of the leading causes of infectious human fatality worldwide. The genome of HIV encodes six viral accessory proteins that are necessary for viral replication and infection. One of these genes, viral infectivity factor (vif), is essential for production of infectious virus. Exactly how this viral protein works within the cell is not clear at present. Current literature suggests that Vif acts in some way to enhance reverse transcription, one of the early stages of the viral l ....HIV-AIDS is still one of the leading causes of infectious human fatality worldwide. The genome of HIV encodes six viral accessory proteins that are necessary for viral replication and infection. One of these genes, viral infectivity factor (vif), is essential for production of infectious virus. Exactly how this viral protein works within the cell is not clear at present. Current literature suggests that Vif acts in some way to enhance reverse transcription, one of the early stages of the viral life cycle. We aim to investigate the action of Vif in stabilizing early HIV reverse transcription complexes to understand how it acts to enhance HIV replication and viral infection. The early stages of HIV replication are critical for establishing infection and hence ideal targets for therapeutic intervention. This research will help understand how Vif works in a cell and affects the infectivity of HIV viral particles and may be suggestive of potential targets for development of anti-viral drugs.Read moreRead less
Gene therapy is a novel form of medical treatment in which healthy genes are used to replace defective genes in cells. It is sobering to realise that in the next few years the whole human DNA sequence will be known. Consequently the already large list of genes which are known to cause disease will be greatly expanded through the application of molecular genetics. Surprisingly, however, treatments based on the correction of disease genes in the cells of a patient are not keeping up with expectati ....Gene therapy is a novel form of medical treatment in which healthy genes are used to replace defective genes in cells. It is sobering to realise that in the next few years the whole human DNA sequence will be known. Consequently the already large list of genes which are known to cause disease will be greatly expanded through the application of molecular genetics. Surprisingly, however, treatments based on the correction of disease genes in the cells of a patient are not keeping up with expectations. In attempting to achieve clinically relevant results, viruses (masters of forcing infected cells to do their bidding) have been harnessed to deliver healthy genes into diseased cells. The problem has been that the modified, safe viruses used clinically have not been efficient at achieving sustained production of healthy genes in sufficient numbers of cells. In the studies described , we will attack this problem using a number of different, but complementary approaches. Our main focus will be to facilitate efficient virus entry of appropriate target cells. We have recently been successful in cloning the receptors for two important viruses which can enter human cells. Identification of these receptors gives us clues to methods of improving virus entry. Now that we know the identity of these receptors, we can create tools to define the type of cells that these viruses can readily target.Read moreRead less